NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	14.73	14.4	10.2	9.93	6.6
Revenue Growth (YoY)	2.24%	41.16%	2.72%	50.54%	-47.24%
Cost of Revenue	6.83	6.62	3.69	3.97	1.74
Gross Profit	7.9	7.78	6.52	5.96	4.86
Selling, General & Admin	12.83	15.29	15.33	12.11	14.08
Research & Development	0.07	0.17	0.04	0.29	0.18
Other Operating Expenses	2.59	6.74	0	0	0
Operating Expenses	15.49	22.2	15.38	12.39	14.26
Operating Income	-7.6	-14.42	-8.86	-6.43	-9.4
Other Expense / Income	2.04	-3.81	-3.04	4.61	0.25
Pretax Income	-9.64	-10.61	-5.82	-11.03	-9.65
Income Tax	0	0	0	0.01	0.01
Net Income	-9.64	-10.61	-5.82	-11.04	-9.66
Preferred Dividends	7.06	5.66	0.74	0	0.83
Net Income Common	-16.7	-16.27	-6.56	-11.04	-10.49
Shares Outstanding (Basic)	0	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0	0
Shares Change	161.80%	29.11%	24.43%	62.08%	26.87%
EPS (Basic)	-138.60	-353.50	-184.10	-379.75	-588.00
EPS (Diluted)	-138.60	-353.50	-184.10	-379.75	-588.00
Free Cash Flow	-4.15	-6.77	-9.24	-4.75	-7.95
Free Cash Flow Per Share	-34.46	-147.09	-259.45	-165.79	-449.90
Gross Margin	53.61%	54.02%	63.85%	60.04%	73.66%
Operating Margin	-51.58%	-100.09%	-86.85%	-64.69%	-142.45%
Profit Margin	-113.38%	-112.92%	-64.28%	-111.12%	-158.92%
Free Cash Flow Margin	-28.18%	-46.97%	-90.59%	-47.79%	-120.44%
EBITDA	-9.44	-10.13	-5.71	-10.98	-9.59
EBITDA Margin	-64.08%	-70.29%	-55.91%	-110.56%	-145.28%
Depreciation & Amortization	0.2	0.48	0.12	0.05	0.07
EBIT	-9.64	-10.61	-5.82	-11.03	-9.65
EBIT Margin	-65.46%	-73.65%	-57.08%	-111.07%	-146.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).